GW-501516 (Cardarine): PPARδ Agonism, Skeletal Muscle Metabolic Reprogramming, and Fatty Acid Oxidation in Research Models
Abstract & Overview GW501516 — also designated GW1516, GSK516, Cardarine, and Endurobol — is a synthetic, orally bioavailable smallmolecule agonist of the peroxisome proliferatoractivated receptor delta (PPARδ), a ligandactivated nuclear transcription factor that serves as a master regulator of fatty acid catabolism, mitochondrial biogenesis, and skeletal muscle fibretype programming. Developed through a collaborative research programme between GlaxoSmithKline and Ligand Pharmaceuticals beginning in 1992, GW501516 was initially investigated as a therapeutic candidate for metabolic syndrome, dyslipidaemia, obesity, and cardiovascular disease [1][2]. The compound displays exceptional receptor selectivity — binding PPARδ with a Ki and EC50 of approximately 1 nM and exhibiting greater than 1,000fold selectivity over the closely related PPARα and PPARγ subtypes [1]. Preclinical studies demonstrated that GW501516 shifts skeletal muscle energy substrate utilisation from glucose to fatty acids, increases the proportion of oxidative slowtwitch muscle fibres, enhances running endurance, improves the lipid profile, and protects against dietinduced obesity and type II diabetes in rodent and primate models [3][4][5]. These properties led to its characterisation as an ‘exercise mimetic’ — a compound capable of pharmacologically replicating certain molecular adaptations of endurance training [4]. “PPARβ/δ agonist and exercise training synergistically increase oxidative myofibers and running endurance in adult mice… AMPKPPARδ pathway can be targeted by orally active drugs to enhance training adaptation or even to increase endurance without exercise.” — Narkar VA et al., Cell (2008) [4]. Despite this compelling preclinical profile, GW501516 was discontinued by GSK in 2007 following the emergence of carcinogenicity data in animal studies, which demonstrated rapid tumour development across multiple organ systems at research doses. The compound has since been added to the World AntiDoping Agency (WADA) prohibited list and has never received regulatory approval for human use. It remains an important research tool for elucidating PPARδ biology and the molecular basis of exercise adaptation [6][7]. Molecular Identity and Structural Architecture GW501516 is a smallmolecule synthetic compound with the molecular formula C₂₁H₁₈F₃NO₃S₂ and a molar mass of 453.49 g/mol (CAS: 317318700; PubChem CID: 9803963; DrugBank: DB05416). Its IUPAC name is {4[({4methyl2[4(trifluoromethyl)phenyl]1,3thiazol5yl}methyl)sulfanyl]2methylphenoxy}acetic acid. The molecule is administered orally and was developed using combinatorial chemistry and structurebased drug design approaches, as reported by Oliver et al. in PNAS (2001) [1]. The structural architecture of GW501516 comprises four key pharmacophoric elements: a 4(trifluoromethyl)phenyl group that anchors the molecule within the PPARδ ligandbinding domain; a 4methyl1,3thiazol5yl heterocyclic core that provides the scaffold for receptor engagement; a thioether (methylsulfanyl) linker connecting the thiazole to the phenoxy moiety; and a 2methylphenoxyacetic acid terminus that contributes to binding affinity and metabolic stability. The trifluoromethyl group is particularly important for selectivity, as it creates hydrophobic contacts within the PPARδ binding pocket that are not accommodated by PPARα or PPARγ [1][2]. The compound’s selectivity profile is exceptional: Ki = 1 nM and EC50 = 1 nM for PPARδ, with greater than 1,000fold selectivity over PPARα and PPARγ. At higher concentrations, some PPARα agonism has been reported, which may contribute to additional lipidlowering effects via hepatic fatty acid oxidation pathways. GW501516 is orally bioavailable and has been used extensively as a research tool to dissect the physiological and pathophysiological functions of PPARδ in metabolic disease models [1][2]. Mechanistic Rationale: PPARδ Activation and Downstream Signalling PPARδ Ligand Binding and PGC1α Coactivator Recruitment Upon oral administration, GW501516 enters the systemic circulation and gains access to target tissues — principally skeletal muscle, adipose tissue, liver, and the cardiovascular system. Within these tissues, GW501516 binds to the ligandbinding domain of PPARδ with nanomolar affinity, inducing a conformational change in the receptor that facilitates recruitment of the transcriptional coactivator peroxisome proliferatoractivated receptor gamma coactivator 1alpha (PGC1α). The resulting PPARδ/PGC1α complex translocates to the nucleus and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, initiating a coordinated transcriptional programme centred on fatty acid catabolism and mitochondrial biogenesis [3][4]. Key transcriptional targets of the GW501516activated PPARδ/PGC1α complex include: carnitine palmitoyltransferase 1 (CPT1), the ratelimiting enzyme for mitochondrial fatty acid import; fatty acid binding protein 3 (FABP3), which facil
For research use only. Not for human consumption.